Silverarc Capital Management’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Silverarc Capital Management’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-12,500	Closed	-$1.27M	–	103
2023 Q2	$1.27M	Buy	+12,500	New	+$1.18M	0.39%	54
2021 Q3	–	Sell	-9,346	Closed	-$1.32K	–	111
2021 Q2	$1.32K	Buy	+9,346	New	+$1.06M	0.59%	61

Other funds holding RETA

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Silverarc Capital Management's RETA Position: Q3 2023 in Review

Silverarc Capital Management sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2023, closing a stake of 12,500 shares — an estimated $1.27M sold.

Silverarc Capital Management first reported a position in RETA in Q2 2021 and held it in 2 quarters. The position peaked at $1.27M in Q2 2023. 2 funds tracked by Wall St. Rank hold RETA as of Q3 2023.

Silverarc Capital Management reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2023 after selling out during the quarter.
Silverarc Capital Management sold 12,500 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2023, an estimated $1.27M.
Silverarc Capital Management first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q2 2021 and held it in 2 quarters.
Silverarc Capital Management's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $1.27M in Q2 2023.
2 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2023.

Based on Silverarc Capital Management's 13F filing for Q3 2023, filed 13 Nov 2023.